Daniel J. George, MD, director of the Prostate Urologic Cancers Program, Duke University Cancer Institute, addresses how genetically defined subgroups, targeted therapies, and immune therapies could have promising effects for prostate cancer patients.
Breakthrough Predictions
25 February 2020, 2:25 EST